N-truncated Aβ peptides in complex fluids unraveled by new specific immunoassays

Neurobiology of Aging

Volumn 34, Issue 2, 2013, Pages 523-539

  Ranaldi, Sébastien ^a   Caillava, Céline ^b   Promé, Sylvie ^a   Rubrecht, Laetitia ^a   Cobo, Sandra ^a   Salvetat, Nicolas ^a   du Paty, Emilie ^a   Galea, Pascale ^a   Aldrian, Gudrun ^c   Le Nguyen, Dung ^a   Krolak Salmon, Pierre ^d   Molina, Franck ^a   Laune, Daniel ^a   Checler, Frédéric ^b   Fareh, Jeannette ^a   Abraham, Jean Daniel ^a  

^a SysDiag CNRS UMR3145   (France)

^b INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c Centre National de la Recherche Scientifique   (France)

^d HOSPICES CIVILS DE LYON   (France)

Author keywords

A PP; Alzheimer's disease; Amyloid; Diagnosis; SELDI; Truncated; XMAP

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[11-40]; AMYLOID BETA PROTEIN[17-40]; BETA SECRETASE; GAMMA SECRETASE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CELL STRAIN HEK293; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; DIFFUSE LEWY BODY DISEASE; ENZYME ACTIVITY; FRONTOTEMPORAL DEMENTIA; HUMAN; IMMUNOASSAY; MULTI NALYTE PROFILING IMMUNOASSAY; PILOT STUDY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN SECRETION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

AGED; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; DEMENTIA; HUMANS; IMMUNOASSAY; MIDDLE AGED; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PILOT PROJECTS; TAU PROTEINS;

EID: 84869096392     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.05.016     Document Type: Article

References (84)

1. Abraham J.D., Calvayrac-Pawlowski S., Cobo S., Salvetat N., Vicat G., Molina L., Touchon J., Michel B.F., Molina F., Verdier J.M., Fareh J., Mourton-Gilles C. Combined measurement of PEDF, haptoglobin and tau in cerebrospinal fluid improves the diagnostic discrimination between alzheimer's disease and other dementias. Biomarkers 2011, 16:161-171.
2. Albertini V., Bruno A., Paterlini A., Lista S., Benussi L., Cereda C., Binetti G., Ghidoni R. Optimization protocol for amyloid-β peptides detection in human cerebrospinal fluid using SELDI TOF MS. Proteomics Clin. Appl 2010, 4:352-357.
3. Ancolio K., Marambaud P., Dauch P., Checler F. Alpha-secretase-derived product of beta-amyloid precursor protein is decreased by presenilin 1 mutations linked to familial Alzheimer's disease. J. Neurochem 1997, 69:2494-2499.
4. Andrau D., Dumanchin-Njock C., Ayral E., Vizzavona J., Farzan M., Boisbrun M., Fulcrand P., Hernandez J.F., Martinez J., Lefranc-Jullien S., Checler F. BACE1- and BACE2-expressing human cells: characterization of beta-amyloid precursor protein-derived catabolites, design of a novel fluorimetric assay, and identification of new in vitro inhibitors. J. Biol. Chem 2003, 278:25859-25866.
5. Andreasen N., Minthon L., Davidsson P., Vanmechelen E., Vanderstichele H., Winblad B., Blennow K. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch. Neurol 2001, 58:373-379.
6. Barelli H., Lebeau A., Vizzavona J., Delaere P., Chevallier N., Drouot C., Marambaud P., Ancolio K., Buxbaum J.D., Khorkova O., Heroux J., Sahasrabudhe S., Martinez J., Warter J.M., Mohr M., Checler F. Characterization of new polyclonal antibodies specific for 40 and 42 amino acid-long amyloid beta peptides: their use to examine the cell biology of presenilins and the immunohistochemistry of sporadic Alzheimer's disease and cerebral amyloid angiopathy cases. Mol. Med 1997, 3:695-707.
7. Barman A., Schürer S., Prabhakar R. Computational modeling of substrate specificity and catalysis of the β-secretase (BACE1) enzyme. Biochemistry 2011, 50:4337-4349.
8. Beher D., Wrigley J.D., Owens A.P., Shearman M.S. Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity. J. Neurochem 2002, 82:563-575.
9. Bibl M., Mollenhauer B., Esselmann H., Lewczuk P., Trenkwalder C., Brechlin P., Rüther E., Kornhuber J., Otto M., Wiltfang J. CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies. J. Neural Transm 2006, 113:1771-1778.
10. Bird T.D. Genetic aspects of Alzheimer disease. Genet. Med 2008, 10:231-239.
11. Blennow K., Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003, 2:605-613.
12. Bradbury L.E., LeBlanc J.F., McCarthy D.B. ProteinChip array-based amyloid beta assays. Methods Mol. Biol 2004, 264:245-257.
13. Buerger K., Zinkowski R., Teipel S.J., Tapiola T., Arai H., Blennow K., Andreasen N., Hofmann-Kiefer K., DeBernardis J., Kerkman D., McCulloch C., Kohnken R., Padberg F., Pirttilä T., Schapiro M.B., Rapoport S.I., Möller H.J., Davies P., Hampel H. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch. Neurol 2002, 59:1267-1272.
14. Buxbaum J.D., Liu K.N., Luo Y., Slack J.L., Stocking K.L., Peschon J.J., Johnson R.S., Castner B.J., Cerretti D.P., Black R.A. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J. Biol. Chem 1998, 273:27765-27767.
15. Cai H., Wang Y., McCarthy D., Wen H., Borchelt D.R., Price D.L., Wong P.C. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat. Neurosci 2001, 4:233-234.
16. Cardebat D., Doyon B., Puel M., Goulet P., Joanette Y. Formal and semantic lexical evocation in normal subjects. Performance and dynamics of production as a function of sex, age and educational level [in French]. Acta Neurol. Belg 1990, 90:207-217.
17. Castaño E.M., Roher A.E., Esh C.L., Kokjohn T.A., Beach T. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol. Res 2006, 28:155-163.
18. Chevallier N., Vizzavona J., Marambaud P., Baur C.P., Spillantini M., Fulcrand P., Martinez J., Goedert M., Vincent J.P., Checler F. Cathepsin D displays in vitro beta-secretase-like specificity. Brain Res 1997, 750:11-19.
19. Cissé M.A., Sunyach C., Lefranc-Jullien S., Postina R., Vincent B., Checler F. The disintegrin ADAM9 indirectly contributes to the physiological processing of cellular prion by modulating ADAM10 activity. J. Biol. Chem 2005, 280:40624-40631.
20. Citron M., Oltersdorf T., Haass C., McConlogue L., Hung A.Y., Seubert P., Vigo-Pelfrey C., Lieberburg I., Selkoe D.J. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 1992, 360:672-674.
21. Colciaghi F., Borroni B., Pastorino L., Marcello E., Zimmermann M., Cattabeni F., Padovani A., Di Luca M. α-Secretase ADAM10 as well as αAPPs is reduced in platelets and CSF of Alzheimer disease patients. Mol. Med 2002, 8:67-74.
22. Colciaghi F., Marcello E., Borroni B., Zimmermann M., Caltagirone C., Cattabeni F., Padovani A., Di Luca M. Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease. Neurology 2004, 62:498-501.
23. Dominguez D.I., Hartmann D., De Strooper B. BACE1 and presenilin: two unusual aspartyl proteases involved in Alzheimer's disease. Neurodegener. Dis 2004, 1:168-174.
24. El Mouedden M., Vandermeeren M., Meert T., Mercken M. Development of a specific ELISA for the quantitative study of amino-terminally truncated beta-amyloid peptides. J. Neurosci. Methods 2005, 145:97-105.
25. Ewers M., Cheng X., Zhong Z., Nural H.F., Walsh C., Meindl T., Teipel S.J., Buerger K., He P., Shen Y., Hampel H. Increased CSF-BACE1 Activity Associated with Decreased Hippocampus Volume in Alzheimer's Disease. J. Alzheimers Dis 2011, 25:373-381.
26. Ewers M., Zhong Z., Bürger K., Wallin A., Blennow K., Teipel S.J., Shen Y., Hampel H. Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain 2008, 131:1252-1258.
27. Flammang B., Pardossi-Piquard R., Sevalle J., Debayle D., Dabert-Gay A.-S., Thevenet A., Lauritzen I., Checler F. Evidence that the amyloid-beta precursor protein intracellular domain AICD derives from beta-secretase generated C-terminal fragment. J. Alzheimers Dis 2012, 30:145-153.
28. Fluhrer R., Multhaup G., Schlicksupp A., Okochi M., Takeda M., Lammich S., Willem M., Westmeyer G., Bode W., Walter J., Haass C. Identification of a beta-secretase activity, which truncates amyloid beta-peptide after its presenilin-dependent generation. J. Biol. Chem 2003, 278:5531-5538.
29. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res 1975, 12:189-198.
30. Frances A., Pincus H.A., Widiger T.A., Davis W.W., First M.B. DSM-IV: work in progress. Am. J. Psychiatry 1990, 147:1439-1448.
31. Francis R., McGrath G., Zhang J., Ruddy D.A., Sym M., Apfeld J., Nicoll M., Maxwell M., Hai B., Ellis M.C., Parks A.L., Xu W., Li J., Gurney M., Myers R.L., Himes C.S., Hiebsch R., Ruble C., Nye J.S., Curtis D. aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev. Cell 2002, 3:85-97.
32. Fukumoto H., Cheung B.S., Hyman B.T., Irizarry M.C. Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch. Neurol 2002, 59:1381-1389.
33. Gelfanova V., Higgs R.E., Dean R.A., Holtzman D.M., Farlow M.R., Siemers E.R., Boodhoo A., Qian Y.W., He X., Jin Z., Fisher D.L., Cox K.L., Hale J.E. Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry. Brief Funct Genomic Proteomic 2007, 6:149-158.
34. Glenner G.G. Alzheimer's disease. The commonest form of amyloidosis. Arch. Pathol. Lab. Med 1983, 107:281-282.
35. Götz J., Schild A., Hoerndli F., Pennanen L. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. Int. J. Dev. Neurosci 2004, 22:453-465.
36. Grober E., Buschke H., Crystal H., Bang S., Dresner R. Screening for dementia by memory testing. Neurology 1988, 38:900-903.
37. Haass C., Lemere C.A., Capell A., Citron M., Seubert P., Schenk D., Lannfelt L., Selkoe D.J. The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nat. Med 1995, 1:1291-1296.
38. Haass C., Schlossmacher M.G., Hung A.Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B.L., Lieberburg I., Koo E.H., Schenk D., Teplow D.B., et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992, 359:322-325.
39. Hansson O., Zetterberg H., Vanmechelen E., Vanderstichele H., Andreasson U., Londos E., Wallin A., Minthon L., Blennow K. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol. Aging 2010, 31:357-367.
40. Holsinger R.M., McLean C.A., Beyreuther K., Masters C.L., Evin G. Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann. Neurol 2002, 51:783-786.
41. Jäger S., Leuchtenberger S., Martin A., Czirr E., Wesselowski J., Dieckmann M., Waldron E., Korth C., Koo E.H., Heneka M., Weggen S., Pietrzik C.U. alpha-secretase mediated conversion of the amyloid precursor protein derived membrane stub C99 to C83 limits Abeta generation. J. Neurochem 2009, 111:1369-1382.
42. Kuhn P.H., Wang H., Dislich B., Colombo A., Zeitschel U., Ellwart J.W., Kremmer E., Rossner S., Lichtenthaler S.F. ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J 2010, 29:3020-3032.
43. Lammich S., Kojro E., Postina R., Gilbert S., Pfeiffer R., Jasionowski M., Haass C., Fahrenholz F. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:3922-3927.
44. Lefranc-Jullien S., Lisowski V., Hernandez J.F., Martinez J., Checler F. Design and characterization of a new cell-permeant inhibitor of the beta-secretase BACE1. Br. J. Pharmacol 2005, 145:228-235.
45. Liu K., Doms R.W., Lee V.M. Glu11 site cleavage and N-terminally truncated A beta production upon BACE overexpression. Biochemistry 2002, 41:3128-3136.
46. Liu K., Solano I., Mann D., Lemere C., Mercken M., Trojanowski J.Q., Lee V.M. Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease. Acta Neuropathol 2006, 112:163-174.
47. Lomas L., Clarke C.H., Thulasiraman V., Fung E. Optimized conditions for a quantitative SELDI TOF MS protein assay. Methods Mol. Biol 2012, 818:1-10.
48. Maarouf C.L., Andacht T.M., Kokjohn T.A., Castaño E.M., Sue L.I., Beach T.G., Roher A.E. Proteomic analysis of Alzheimer's disease cerebrospinal fluid from neuropathologically diagnosed subjects. Curr. Alzheimer Res 2009, 6:399-406.
49. Maddalena A.S., Papassotiropoulos A., Gonzalez-Agosti C., Signorell A., Hegi T., Pasch T., Nitsch R.M., Hock C. Cerebrospinal fluid profile of amyloid beta peptides in patients with Alzheimer's disease determined by protein biochip technology. Neurodegener. Dis 2004, 1:231-235.
50. Mattsson N., Zetterberg H., Hansson O., Andreasen N., Parnetti L., Jonsson M., Herukka S.K., van der Flier W.M., Blankenstein M.A., Ewers M., Rich K., Kaiser E., Verbeek M., Tsolaki M., Mulugeta E., Rosén E., Aarsland D., Visser P.J., Schröder J., Marcusson J., de Leon M., Hampel H., Scheltens P., Pirttilä T., Wallin A., Jönhagen M.E., Minthon L., Winblad B., Blennow K. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009, 302:385-393.
51. McKeith I.G., Dickson D.W., et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005, 65(12):1863-1872.
52. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
53. Mulder S.D., van der Flier W.M., Verheijen J.H., Mulder C., Scheltens P., Blankenstein M.A., Hack C.E., Veerhuis R. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. J. Alzheimers Dis 2010, 20:253-260.
54. Näslund J., Karlström A.R., Tjernberg L.O., Schierhorn A., Terenius L., Nordstedt C. High-resolution separation of amyloid beta-peptides: structural variants present in Alzheimer's disease amyloid. J. Neurochem 1996, 67:294-301.
55. Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Kertesz A., Robert P.H., Albert M., Boone K., Miller B.L., Cummings J., Benson D.F. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998, 51:1546-1554.
56. Olsson A., Vanderstichele H., Andreasen N., De Meyer G., Wallin A., Holmberg B., Rosengren L., Vanmechelen E., Blennow K. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin. Chem 2005, 51:336-345.
57. Portelius E., Dean R.A., Gustavsson M.K., Andreasson U., Zetterberg H., Siemers E., Blennow K. A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease. Alzheimers Res. Ther 2010, 2:7.
58. Portelius E., Price E., Brinkmalm G., Stiteler M., Olsson M., Persson R., Westman-Brinkmalm A., Zetterberg H., Simon A.J., Blennow K. A novel pathway for amyloid precursor protein processing. Neurobiol. Aging 2011, 32:1090-1098.
59. Portelius E., Zetterberg H., Andreasson U., Brinkmalm G., Andreasen N., Wallin A., Westman-Brinkmalm A., Blennow K. An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid. Neurosci. Lett 2006, 409:215-219.
60. Postina R. A closer look at alpha-secretase. Curr. Alzheimer Res 2008, 5:179-186.
61. Qahwash I., He W., Tomasselli A., Kletzien R.F., Yan R. Processing amyloid precursor protein at the beta-site requires proper orientation to be accessed by BACE1. J. Biol. Chem 2004, 279:39010-39016.
62. Reig S., Buée-Scherrer V., Mourton-Gilles C., Defossez A., Delacourte A., Beauvillain J.C., Mazzuca M. Immunogold labelling of paired helical filaments and amyloid fibrils by specific monoclonal and polyclonal antibodies. Acta Neuropathol 1995, 90:441-447.
63. Reitan R.M., Herring S. A short screening device for identification of cerebral dysfunction in children. J. Clin. Psychol 1985, 41:643-650.
64. Saido T.C., Iwatsubo T., Mann D.M., Shimada H., Ihara Y., Kawashima S. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron 1995, 14:457-466.
65. Saido T.C., Yamao-Harigaya W., Iwatsubo T., Kawashima S. Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci. Lett 1996, 215:173-176.
66. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 1991, 6:487-498.
67. Sennvik K., Fastbom J., Blomberg M., Wahlund L.O., Winblad B., Benedikz E. Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients. Neurosci. Lett 2000, 278:169-172.
68. Sergeant N., Bombois S., Ghestem A., Drobecq H., Kostanjevecki V., Missiaen C., Wattez A., David J.P., Vanmechelen E., Sergheraert C., Delacourte A. Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. J. Neurochem 2003, 85:1581-1591.
69. Sergeant N., David J.P., Champain D., Ghestem A., Wattez A., Delacourte A. Progressive decrease of amyloid precursor protein carboxy terminal fragments (APP-CTFs), associated with tau pathology stages, in Alzheimer's disease. J. Neurochem 2002, 81:663-672.
70. Sevalle J., Amoyel A., Robert P., Fournié-Zaluski M.C., Roques B., Checler F. Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptide. J. Neurochem 2009, 109:248-256.
71. Shi X.P., Tugusheva K., Bruce J.E., Lucka A., Wu G.X., Chen-Dodson E., Price E., Li Y., Xu M., Huang Q., Sardana M.K., Hazuda D.J. Beta-secretase cleavage at amino acid residue 34 in the amyloid beta peptide is dependent upon gamma-secretase activity. J. Biol. Chem 2003, 278:21286-21294.
72. Simonsen A.H., McGuire J., Hansson O., Zetterberg H., Podust V.N., Davies H.A., Waldemar G., Minthon L., Blennow K. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch. Neurol 2007, 64:366-370.
73. Steidel M., Fragnoud R., Guillotte M., Roesch C., Michel S., Meunier T., Paranhos-Baccalà G., Gervasi G., Bedin F. Nonstructural protein NS1 immunodominant epitope detected specifically in dengue virus infected material by a SELDI-TOF/MS based assay. J. Med. Virol 2012, 84:490-499.
74. Takahashi E., Howe A., Vesterqvist O., Lin Z. Quantitation of amyloid beta peptides in CSF by surface enhanced MALDI-TOF. Methods Mol. Biol 2012, 818:227-236.
75. Takasugi N., Tomita T., Hayashi I., Tsuruoka M., Niimura M., Takahashi Y., Thinakaran G., Iwatsubo T. The role of presenilin cofactors in the gamma-secretase complex. Nature 2003, 422:438-441.
76. Vandermeeren M., Mercken M., Vanmechelen E., Six J., van de Voorde A., Martin J.J., Cras P. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J. Neurochem 1993, 61:1828-1834.
77. Vanderstichele H., De Vreese K., Blennow K., Andreasen N., Sindic C., Ivanoiu A., Hampel H., Bürger K., Parnetti L., Lanari A., Padovani A., DiLuca M., Bläser M., Olsson A.O., Pottel H., Hulstaert F., Vanmechelen E. Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin. Chem. Lab. Med 2006, 44:1472-1480.
78. Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., Teplow D.B., Ross S., Amarante P., Loeloff R., Luo Y., Fisher S., Fuller J., Edenson S., Lile J., Jarosinski M.A., Biere A.L., Curran E., Burgess T., Louis J.C., Collins F., Treanor J., Rogers G., Citron M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286:735-741.
79. Vetrivel K.S., Barman A., Chen Y., Nguyen P.D., Wagner S.L., Prabhakar R., Thinakaran G. Loss of cleavage at β'-site contributes to apparent increase in β-amyloid peptide (Aβ) secretion by β-secretase (BACE1)-glycosylphosphatidylinositol (GPI) processing of amyloid precursor protein. J. Biol. Chem 2011, 286:26166-26177.
80. Wagner M., Wolf S., Reischies F.M., Daerr M., Wolfsgruber S., Jessen F., Popp J., Maier W., Hüll M., Frölich L., Hampel H., Perneczky R., Peters O., Jahn H., Luckhaus C., Gertz H.J., Schröder J., Pantel J., Lewczuk P., Kornhuber J., Wiltfang J. Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. Neurology 2012, 78:379-386.
81. Xia W., Zhang J., Ostaszewski B.L., Kimberly W.T., Seubert P., Koo E.H., Shen J., Selkoe D.J. Presenilin 1 regulates the processing of beta-amyloid precursor protein C-terminal fragments and the generation of amyloid beta-protein in endoplasmic reticulum and Golgi. Biochemistry 1998, 37:16465-16471.
82. Yamakawa H., Yagishita S., Futai E., Ishiura S. beta-Secretase inhibitor potency is decreased by aberrant beta-cleavage location of the "Swedish mutant" amyloid precursor protein. J. Biol. Chem 2010, 285:1634-1642.
83. Zetterberg H., Andreasson U., Hansson O., Wu G., Sankaranarayanan S., Andersson M.E., Buchhave P., Londos E., Umek R.M., Minthon L., Simon A.J., Blennow K. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch. Neurol 2008, 65:1102-1107.
84. Zhang J., Goodlett D.R., Quinn J.F., Peskind E., Kaye J.A., Zhou Y., Pan C., Yi E., Eng J., Wang Q., Aebersold R.H., Montine T.J. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J. Alzheimers Dis 2005, 7:125-133. Discussion, 173-180.